A plasma proteomic frailty signature for cardiovascular risk stratification: A multi-cohort study
Related Experiment Video
Updated: Nov 10, 2026
Isolation, Characterization, and Proteomic Analysis of Plasma-Derived Extracellular Vesicles for Cardiovascular Biomarker Discovery
Published on: January 31, 2025
Pingjing Zheng1,2,3,4, Jiabo Wu5, Xiaoqing Gu6
1Department of Cardiology, State Key Laboratory of Cardiovascular Diseases, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China.
Background:
Frailty predicts adverse health outcomes, but its relationship with cardiovascular disease (CVD) requires further validation across diverse populations. The value of a circulating protein signature for cardiovascular risk assessment remains uncertain.
Methods:
We examined frailty-CVD associations in the XiDu2017 cohort (n = 4323) and UK Biobank (UKB; n = 84,276) using logistic and Cox regression, respectively. XiDu longitudinal analyses included 844 participants without baseline CVD. In the UKB proteomic subset, a 20-protein frailty (PF) score was compared with clinical frailty and a model of conventional cardiovascular risk factors.
Results:
Each higher frailty category was associated with prevalent CVD in XiDu (adjusted odds ratio, 1.120; 95% confidence interval [CI], 1.004-1.251). In UKB, frail participants had a higher CVD hazard than robust participants (adjusted hazard ratio, 1.38; 95% CI, 1.28-1.48). For heart failure, the 5-year area under the curve (AUC) was 0.756 for PF and 0.595 for clinical frailty. Adding PF to conventional risk factors increased the optimism-corrected heart failure AUC by 0.113 (95% CI, 0.077-0.142).
Conclusions:
Clinical frailty was associated with cardiovascular outcomes in both cohorts. PF showed incremental discrimination for selected outcomes, particularly heart failure. External validation and evaluation of clinical utility are needed before clinical application.
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...